1 / 11

Oxford Bioscience Partners New Licensing Deal Structures: Strategies

Oxford Bioscience Partners New Licensing Deal Structures: Strategies And Tactics for Successful Business Development Dr B J Bormann, Vice President Strategic Alliances May 25, 2005. Then : most research conducted in-house. 1990’s: collaborations were not the “norm” in pharma

dwilcox
Download Presentation

Oxford Bioscience Partners New Licensing Deal Structures: Strategies

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Oxford Bioscience Partners New Licensing Deal Structures: Strategies And Tactics for Successful Business Development Dr B J Bormann, Vice President Strategic AlliancesMay 25, 2005

  2. Then : most research conducted in-house • 1990’s: collaborations were not the “norm” in pharma “I’m amazed at the arrogance of some U.S. pharmaceutical companies like Merck and Pfizer who have hardly cut any deals with biotechnology companies. That’s a very strange decision.” Tim Wilson, Analyst, UBS Securities, New York, BioWorld Today, August 1996

  3. Adding value: the SA vision • Our alliance investments : • Are integrated and aligned with our global strategies, initiatives and internal investments • Address opportunities and gaps to create competitive advantage • Enable the low-cost evaluation of novel opportunities • Provide access to novel technologies with the potential to change the current R&D paradigm • Are managed with respect to the science, business, legal and IP issues • Are assessed and monitored with appropriate metrics “Cradle to grave alliance management”

  4. Quorex • Vicuron • ISIS • Renovis • Oxford Biosensors • Perlegen • Bend • Chondrogene • Chromos • Sangamo • Virtual Scopics • Odyssey Thera • ActivX • PA Consulting/Engineering • Codexis • Genestruct • Jubilant • Lifespan SA Portfolio – Aligned along 04/05 Strategic Themes 2005 Strategic Investment Themes Recent Investments CAN Producing Collaborations Productivity TA Enablers Emerging Sciences Leveraging Scale Cross-line investments Speed/Efficiency/ Process

  5. Research Technology Line (STWGs) TA Enablers Biomarkers DDF KM PGX Automation Biologicals Chemistry CIR CIS PK-PD SA Portfolio Mix Imaging • Amersham • LifeSpan • Scimagix • Synarc Autom Chem • Argonaut • Accendo • Foster-Miller • Mettler-Toled • PA Engg • TAP Ab platforms • Medarex • Abgenix • Morphosys • CAT • Increase CIR/CIS • Biovation • Chondrogene • Production/ • Scale-up • BI • Cambrex Bio • GTC Therap • Lonza • Delivery • Atrix • Macrocrystal • Transform Parallel Chem • Accendo • Argonaut • Avantium • ArQule • ChemBridge • Codexis • DPI • Metabolix • Tripos • Separation Technology • U Ghent • BioTage • Str Elucidat/ • Physical Prop. • Scimagix • Foster-Miller • AMRI • In silico • Entelos • Bioprint/ • Cerep • Informatics • Bend • Pharmacopia ADME • Xenoport Animal Mod GeMMs • Xenogen • Deltagen • genOway • Lexicon • Mayo RNAi • Cold Spring Harbor Stem Cells • Stem Cell Sci Structural Bio • Affinium • Joslin • Targets • Kinases • Systems Bio U Toronto U Colorado Flinders Originus Leiden GenPharm Karolinska • Diagnostics • Beacon Bio • Oxford • Amersham • CogState • Pharsight • Source Presicion • Immunicon • Neurosol • Imaging • VirtualScop • MIICRO • Yale • Nat Ins Age • Kestrel • King’s College SDD • Bend OCR • Andrx • SkyePharm • Protein Del • Nektar • Atrix • Bend • Nobex • Devices • Meridica • Injex • Aradigm Pulmonary • Meridica • Ventaira • Bend • Astechr • Nektar • Biowisdon • Genstruct • PharmaMat • Epidauras • Genaissance • Perlegen • ViroLogic • Source precision CV/QT • Neurion • Yeragani GeneTox • UCLA Immunotox • U Maryland • Immunotox • Biovation Metabonomics • ChenomX • Bruker • Metabometri • Lipomics • Varian Pathology • LifeSpan • Toxico-panomics • Affymetrix • Gene Logic • LION • LHASA • HTG • Ciphergen • CuraGen Many TWG & TA Enabler technology investments impact multiple TAs; hence TAs are not shown here

  6. SA collaborations that have impacted CANs/Compounds/Programs Collaboration TAs/Programs/Targets Impacted • NMDA Antagonist, NNOS Inhibitor • OA, RA, Oncology; Imaging for clinical trials • Duke Univ • Virtual Scopics CLINICAL • Brains-on-Line • UCSD – Dr. Olefsky • Wake Forest Univ. DISCOVERY • NRI/SRI programs; 5HT2C, CB-1, D3 targets • PPAR alpha/gamma • CETP; PDE(V); MTP; LDL-C reduction PDM • Multi-cell Technology • NK-1 antagonist WWPS • Bend Research • Meridica • QLT • Multiple • A&R • Bone Regeneration WWSS • MPI Research • PPAR alpha/gamma

  7. SA Impact on the PGRD pipeline LD CS Pre Clinical Phase I Phase IIa LD CS Pre - - Clinical Phase I POP LAN CAN IND POC POC 9/05 9/05 9/06 Alliance Date Therapeutic Area/ Target 12/97 Imm/CTLA4 Onc/CD40 Onc/IGFR IBD RA Onc Hem/Onc Inflamm. 11/99 12/01 12/04 ABGENIX 9/01 3/04 11/00 12/03 6/05 11/03 6/05 11/03 OSIP Onc/VEGF Onc Onc 6/03 2/96 6/03 6/03 CVMD Vit D Analogs 6/03 4/04 12/04 DELTANOID 12/02 CNS/GABA 8/97 1/99 1/01 11/95 12/91 NEUROGEN 12/00 1/02 Anti-viral HIV Protease 11/00 JAPAN ENRG. 12/98 VICURON 3/99 Anti-bacterial Multiple 10/05 6/04 6/04

  8. Global Research and DevelopmentMajorAlliance Partnerships: June 2005 Speeding/Enhancing DevelopmentCandidates Enhancing Pipeline Value Altering the R&D Productivity Paradigm Product Enhancement Gene Function Screen Lead Candidate Development Speed Affinium Athersys Celera Chondrogene Metabolex Karolinska U. Pittsburgh Wash. U Xenon Biotica Deltanoid Japan Energy Neurion Vicuron Wake Forest Virologic Rigel Nicox Angiosyn Idun Coley Renovis Amersham U. Cambridge Curagen GeneLogic Lonza Miicro Meridica Kings Pain Ctr NIA Virtual Scopics Yale Symyx Boehringer Ingelheim Chromos Avantium Foster Miller PA Auto/Eng U. Michigan Biowisdom ProModel Genestruct Codexis Perlegen Lifespan Alza Atrix (QTL) Battelle Bend Nektar Freie Univ. U. Rochester Oxford Biosensors Abgenix ArQule CB Research ChemBridge ChemRx Cerep Entelos Naeja Peakdale Mol Piedmont Spotfire Tripos Medarex Morphosys Quorex Isis Affymetrix Deltagen InPharmatica Xenogen Lexicon Gen Chondrogene Cerep Biotrove C.A.T. Evotec Stem Cell Sci U. Dundee Xenoport Lilly ActivX Sangamo Odyssey Th.

  9. Innovative Deal Structures? From the previous list, how many are truly innovative? It is all relative……… For most of us, not a lot of innovation For Pfizer, there are some remarkable degrees of freedom here Central element for Pfizer is not $$, but options and control

  10. 2005 Pharmaceutical Achievement Awards Finalist List Business Development Deal of the Year Astra Zeneca and Cambridge Antibody Technology Pfizer Inc and Medarex Theravance and GlaxoSmithKline Dealmaking Theravance: Having Cake and Eating It

  11. Innovative Deal Structures: On Horizon What can you expect to see from Pfizer: Acquisitions of small/medium companies Not just potential products, platform technologies too Perhaps with pre-arranged spin outs More ‘Horse-trading’ Cross-licenses Pooling programs Future calls on IP More Option Agreements E.g. support platform technology development now Option to take in house, option for compounds Advice: Think about what we can offer you other than $$

More Related